High Dose CHOP in Lymphoma

Rambam Health Care Campus

Status and phase: Completed; Phase 2

Conditions: Non-Hodgkin's Lymphoma

Treatments: Drug: high-dose cyclophosphamide

Study type: Interventional

Funder types: Other

Identifiers

NCT00192764

RonHDCHOP.CTIL

Details and patient eligibility

About

The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• large-cell non-Hodgkin's lymphoma
• IPI low-intermediate, high-intermediate and high or bulky mediastinum
• age 18-65

Exclusion criteria

• previous treatment for lymphoma
• serious concurrent systemic disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)